title: Clinical significance of serum and urinary HER2/neu protein levels in primary non-muscle invasive bladder cancer.
abstract: OBJECTIVE
  We aimed to compare serum and urinary HER2/neu levels between healthy control group and patients with non-muscle invasive bladder cancer. Additionally, we evaluated relationship of HER2/neu levels with tumor stage, grade, recurrence and progression.
  
  
  METHODS
  Fourty-four patients with primary non-muscle invasive bladder tumors (Group 2) and 40 healthy control group (Group 1) were included the study. Blood and urinary samples were collected from all patients and HER2/neu levels were measured by ELISA method. Blood and urinary HER2/neu levels and additionally, ratio of urinary HER2/neu levels to urinary creatinine levels were recorded. Demographic data and tumor characteristics were recorded.
  
  
  RESULTS
  Mean serum HER2/neu levels were similar between two groups and statistically significant difference wasn't observed. Urinary HER2/neu levels were significantly higher in group 2 than group 1. Ratio of urinary HER2/neu to urinary creatinine was significantly higher in group 2 than group 1, (p=0,021). Serum and urinary HER2/ neu levels were not associated with tumor stage, grade, recurrence and progression while ratio of urinary HER2/neu to urinary creatinin levels were significantly higher in high-grade tumors. HER2/neu, the sensitivity of the test was found to be 20.5%, and the specificity was 97.5%, also for the urinary HER2/neu/urinary creatinine ratio, the sensitivity and specificity of the test were found to be 31.8% and 87.5%, respectively.
  
  
  CONCLUSIONS
  Urinary HER2/neu and ratio of urinary creatinine urine were significantly higher in patients with bladder cancer compared to healthy subjects. Large series and controlled studies are needed for use as a tumor marker.
authors.affiliation: Department of Urology, Nigde Bor State Hospital, Bor Nigde, Istanbul, Turkey.
authors.forename: Ozgur
authors.initials: O
authors.lastname: Arikan
authors.affiliation: Department of Urology, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey.
authors.forename: Asýf
authors.initials: A
authors.lastname: Yýldýrým
authors.affiliation: Department of Biochemistry, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey.
authors.forename: Banu
authors.initials: B
authors.lastname: Ýsbilen
authors.affiliation: Department of Urology, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey.
authors.forename: Cengiz
authors.initials: C
authors.lastname: Canakci
authors.affiliation: Department of Urology, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey.
authors.forename: Gokhan
authors.initials: G
authors.lastname: Atýs
authors.affiliation: Department of Urology, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey.
authors.forename: Cenk
authors.initials: C
authors.lastname: Gurbuz
authors.affiliation: Department of Urology, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey.
authors.forename: Bulent
authors.initials: B
authors.lastname: Erol
authors.affiliation: Department of Biochemistry, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey.
authors.forename: Ferruh Kemal
authors.initials: FK
authors.lastname: Ýsman
authors.affiliation: Department of Pathology, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey.
authors.forename: Seyma
authors.initials: S
authors.lastname: Ozkanli
authors.affiliation: Department of Urology, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey.
authors.forename: Turhan
authors.initials: T
authors.lastname: Caskurlu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D015992:Body Mass Index; D002295:Carcinoma, Transitional Cell / Q000473:pathology*; D016022:Case-Control Studies; D003404:Creatinine / Q000652:urine; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood* / Q000652:urine*; D012680:Sensitivity and Specificity; D047368:Tumor Burden; D001749:Urinary Bladder Neoplasms / Q000473:pathology*
chemical_list: D014408:Biomarkers, Tumor; D003404:Creatinine; D018719:Erb-b2 Receptor Tyrosine Kinases